TY - JOUR
T1 - The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
AU - Hillmen, Peter
AU - Young, Neal S.
AU - Schubert, Jörg
AU - Brodsky, Robert A.
AU - Socié, Gerard
AU - Muus, Petra
AU - Röth, Alexander
AU - Szer, Jeffrey
AU - Elebute, Modupe O.
AU - Nakamura, Ryotaro
AU - Browne, Paul
AU - Risitano, Antonio M.
AU - Hill, Anita
AU - Schrezenmeier, Hubert
AU - Fu, Chieh Lin
AU - Maciejewski, Jaroslaw
AU - Rollins, Scott A.
AU - Mojcik, Christopher F.
AU - Rother, Russell P.
AU - Luzzatto, Lucio
PY - 2006/9/21
Y1 - 2006/9/21
N2 - BACKGROUND: We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH). METHODS: We conducted a double-blind, randomized, placebo-controlled, multicenter, phase 3 trial. Patients received either placebo or eculizumab intravenously; eculizumab was given at a dose of 600 mg weekly for 4 weeks, followed 1 week later by a 900-mg dose and then 900 mg every other week through week 26. The two primary end points were the stabilization of hemoglobin levels and the number of units of packed red cells transfused. Biochemical indicators of intravascular hemolysis and the patients' quality of life were also assessed. RESULTS: Eighty-seven patients underwent randomization. Stabilization of hemoglobin levels in the absence of transfusions was achieved in 49% (21 of 43) of the patients assigned to eculizumab and none (0 of 44) of those assigned to placebo (P<0.001). During the study, a median of 0 units of packed red cells was administered in the eculizumab group, as compared with 10 units in the placebo group (P<0.001). Eculizumab reduced intravascular hemolysis, as shown by the 85.8% lower median area under the curve for lactate dehydrogenase plotted against time (in days) in the eculizumab group, as compared with the placebo group (58,587 vs. 411,822 U per liter; P<0.001). Clinically significant improvements were also found in the quality of life, as measured by scores on the Functional Assessment of Chronic Illness Therapy-Fatigue instrument (P<0.001) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Of the 87 patients, 4 in the eculizumab group and 9 in the placebo group had serious adverse events, none of which were considered to be treatment-related; all these patients recovered without sequelae. CONCLUSIONS: Eculizumab is an effective therapy for PNH. (ClinicalTrials.gov number, NCT00122330.)
AB - BACKGROUND: We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH). METHODS: We conducted a double-blind, randomized, placebo-controlled, multicenter, phase 3 trial. Patients received either placebo or eculizumab intravenously; eculizumab was given at a dose of 600 mg weekly for 4 weeks, followed 1 week later by a 900-mg dose and then 900 mg every other week through week 26. The two primary end points were the stabilization of hemoglobin levels and the number of units of packed red cells transfused. Biochemical indicators of intravascular hemolysis and the patients' quality of life were also assessed. RESULTS: Eighty-seven patients underwent randomization. Stabilization of hemoglobin levels in the absence of transfusions was achieved in 49% (21 of 43) of the patients assigned to eculizumab and none (0 of 44) of those assigned to placebo (P<0.001). During the study, a median of 0 units of packed red cells was administered in the eculizumab group, as compared with 10 units in the placebo group (P<0.001). Eculizumab reduced intravascular hemolysis, as shown by the 85.8% lower median area under the curve for lactate dehydrogenase plotted against time (in days) in the eculizumab group, as compared with the placebo group (58,587 vs. 411,822 U per liter; P<0.001). Clinically significant improvements were also found in the quality of life, as measured by scores on the Functional Assessment of Chronic Illness Therapy-Fatigue instrument (P<0.001) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Of the 87 patients, 4 in the eculizumab group and 9 in the placebo group had serious adverse events, none of which were considered to be treatment-related; all these patients recovered without sequelae. CONCLUSIONS: Eculizumab is an effective therapy for PNH. (ClinicalTrials.gov number, NCT00122330.)
UR - http://www.scopus.com/inward/record.url?scp=33748904355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748904355&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa061648
DO - 10.1056/NEJMoa061648
M3 - Article
C2 - 16990386
AN - SCOPUS:33748904355
SN - 0028-4793
VL - 355
SP - 1233
EP - 1243
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 12
ER -